Perisoxal citrate is a basic nonsteroidal anti-inflammatory and analgesic drug.

Mosapride is a gastroprokinetic agent, a 5-HT4 receptor agonist and 5-HT3 receptor antagonist exhibiting no activity at dopamine D2, 5-HT1 and 5-HT2 receptors. Mosapride stimulates serotonin receptor in the digestive tract and increases acetylcholine release to promote upper digestive tract (stomach and duodenum) and lower digestive tract (colon) motility. It is usually used to treat heartburn, nausea and vomiting caused by chronic gastritis. Mosapride is approved and marketed in the countires of Asia and Latin America.

Isoaminile is a cough suppressant that acts by influencing the cough centre.

Mosapride is a gastroprokinetic agent, a 5-HT4 receptor agonist and 5-HT3 receptor antagonist exhibiting no activity at dopamine D2, 5-HT1 and 5-HT2 receptors. Mosapride stimulates serotonin receptor in the digestive tract and increases acetylcholine release to promote upper digestive tract (stomach and duodenum) and lower digestive tract (colon) motility. It is usually used to treat heartburn, nausea and vomiting caused by chronic gastritis. Mosapride is approved and marketed in the countires of Asia and Latin America.

Fe-59 is an isotope of iron. It has a half-life of 44.5 days and decays by emitting a beta particle. In medicine, ferrous citrate Fe 59 is indicated, by intravenous administration, to determine various parameters of the kinetics of iron metabolism, including plasma iron clearance, plasma iron turnover rate, and the utilization of iron in new red blood cells. An oxidized form of iron cation, ferric cation Fe59, is also used to study the processes of iron metabolism.

Butetamate is a cough suppressant. It exerts antispasmodic, bronchodilator and anticholinergic properties.

Oxeladin citrate is a cough suppressant, is a highly potent and effective drug used to treat all types of cough of various etiologies. Withdrawn from the Canadian, US, and UK markets in 1976 due to carcinogenicity. Oxeladine is a component of antitussive drug, Altussan, approved in Philippines.

Cetiedil is effective potassium channel blocker used as a peripheral vasodilator to treat patients with painful crises in sickle cell anemia and pain in the extremities caused by an arterial disease. Known pharmacological properties of the drug include vascular smooth muscle relaxation, inhibition of phosphodiesterase with the consequent increase in circulating cyclic AMP concentration, blockade of the effect of bradykinin and serotonin, analgesia, inhibition of platelet aggregation and the decrease of plasma and blood viscosity and plasma fibrinogen level. The antisickling effect of cetiedil is explained mainly in the light of the changes it induces in the activities of membrane-bound ATPases and the permeability properties of the erythrocyte membrane to cations and anions.

Butamirate (or brospamin) is a medicine used for the symptomatic treatment of non-productive (dry) cough. Butamirate is centrally acting cough suppressant which is neither chemically nor pharmacologically related to opium alkaloids. In addition to its antitussive effect, Butamirate also decreases the airway resistance. Butamirate is rapidly and completely absorbed after oral administration. Maximum concentration is reached within 9 hours with sustain release tablet. Butamirate is extremely protein bound and Plasma elimination half-life is about 13 hours. Butamirate is indicated in acute cough of any etiology, pre and post operative cough sedation for surgical procedure and bronchoscopy. Butamirate is well tolerated. In rare cases, skin rash, nausea, diarrhea, dizziness have been reported.They disappear after reduction of the dosage or discontinuation of the drug.

Bunaftine is a class III antiarrhythmic agent which has been found effective in treating or preventing both ventricular and supraventricular arrhythmias. The acute electrophysiologic effects of intravenous Bunaphtine 1,5 mg/kg body weight, were studied in 19 subjects with estimated normal impulse formation and conduction. Significant effects were sinus bradycardia, prolongation of atrial refractory periods, depression of intranodal and infranodal conduction and prolongation of His-Purkinje system refractory periods. These properties are compared with those of amiodarone and quinidine and form the basis for correct use of Bunaphtine in the management of arrhythmias